SJ-300

Overview

SJ-300 is a potent and selective, orally active and brain-penetrat DKK3-LRP1 interaction inhibitor. SJ-300 restores Aβ clearance in AD models. SJ 300 binds to mLRPIV with a K d of 7.9 μM, inhibits the DKK3 mLRPIV complex with an IC 50 of 3.2 μM, and does not disrupt the binding of Aβ to LRP1 . SJ 300 rescues cognitive function and ameliorates neuropathology ( Aβ plaque reduction ≈ 73.3 %) in vivo. SJ 300 can be employed for research in Alzheimer’s disease.

Application

Products | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Wnt | Products > Signaling Pathways > LDLR | Products > Signaling Pathways > Amyloid-β

Product Information

• Catalog No.: HY-179459
• CAS No.: 1210357-06-4
• Molecular Formula: C20H27FN4
• Molecular Weight: 342.45
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source